Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12909616
Balasubramanian S, Kuppuswamy D (2003) RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J Biol Chem 278, 42214-24 12909616
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
insulin increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

Y397-p - FAK (human)
Modsite: sVsEtDDyAEIIDEE SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y397‑p, FAK iso2 (mouse): Y428‑p, FAK iso4 (mouse): Y397‑p, FAK iso9 (mouse): , FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD no change compared to control 2-D laminin-coated surface
RGD increase 3-D collagen matrix

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD no effect upon treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD inhibit treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
wortmannin RGD inhibit treatment-induced increase
rapamycin RGD inhibit treatment-induced increase
monensin RGD inhibit treatment-induced increase
monodansylcadaverine RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD inhibit treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
wortmannin RGD inhibit treatment-induced increase
rapamycin RGD no effect upon treatment-induced increase
monensin RGD inhibit treatment-induced increase
monodansylcadaverine RGD no effect upon treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
anti-ITGB3 RGD inhibit treatment-induced increase
anti-ITGB1 RGD no effect upon treatment-induced increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD inhibit treatment-induced increase
wortmannin RGD inhibit treatment-induced increase
rapamycin RGD no effect upon treatment-induced increase
monensin RGD inhibit treatment-induced increase
monodansylcadaverine RGD no effect upon treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD no effect upon treatment-induced increase
wortmannin RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
bisindolylmaleimide RGD no effect upon treatment-induced increase
U0126 RGD no effect upon treatment-induced increase
wortmannin RGD inhibit treatment-induced increase
phorbol_ester increase
bisindolylmaleimide phorbol_ester inhibit treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
insulin increase
wortmannin insulin inhibit treatment-induced increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cells
Species studied:  cat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD no change compared to control 2-D laminin-coated surface
RGD increase 3-D collagen matrix